Pfizer Inc. (PFE)
Why Pfizer (PFE) Outpaced the Stock Market Today
In the most recent trading session, Pfizer (PFE) closed at $26.64, indicating a +1.29% shift from the previous trading day.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer CEO: Americans can expect radical change from this upcoming Trump administration
Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S. president, becoming the second to serve two non-consecutive terms.
3 Upcoming Dividend Increases
This week's anticipated dividend increases feature three companies with an average increase of 8.9% and a median increase of 8.7%. My strategy focuses on buying, holding, and adding companies that consistently increase dividends and outperform benchmarks. I use data from U.S. Dividend Champions and NASDAQ to guide my decisions. I prioritize stocks with strong historical performance and dividend growth, comparing them against benchmarks like SCHD and RNP for non-REITs and REITs, respectively.
What To Expect From PFE Stock In 2025?
Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly stock (up 31%) and AbbVie stock (up 15%), Pfizer's stock performance has been muted.
Why Pfizer sold its $3 billion stake in Haleon
Pfizer's decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each, reduced Pfizer's ownership in the British consumer healthcare giant to 7.3%.
Pfizer to further reduce stake in Haleon through share sale
Pfizer Inc (NYSE:PFE, ETR:PFE) plans to sell around 700 million shares of Haleon PLC (LSE:HLN, NYSE:HLN), representing a 7.7% stake, via a secondary offering through an accelerated book-building process targeting institutional investors. Currently holding 15% of the Panadol maker, Pfizer expects to reduce its interest to about 7.3 per cent upon completion.
Pfizer Sells 700 Million Haleon Shares for $3 Billion
The sale decreases Pfizer's shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
Pfizer (PFE) reachead $26.41 at the closing of the latest trading day, reflecting a -1.46% change compared to its last close.
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A. Cohen's former hedge fund, SAC Capital Management.
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. PFE Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.”
Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer intends to sell about 700 million ordinary shares in Haleon , cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday.
